Grant: Engage Grants Program
Dalhousie University
$24,500.00
Direct Preparation of Key Intermediates in Heterocycle Synthesis Employing Novel Pd-Catalyzed Alpha-Arylation
EF 2011-12
Résumé
The majority of pharmaceutical compounds derive their beneficial properties from the presence of a
nitrogen-containing heterocyclic core structure. As such, the development of novel routes to such heterocyclic
structural motifs, or their direct precursors, represents an important challenge in the quest to advance the drug
discovery process. Furthermore, the establishment of synthetic protocols that are efficient and modular in
nature, and that exploit cheap and abundant reagents, are particularly attractive in terms of streamlining and
diversifying the assembly of heterocyclic core structures, as well as in facilitating reductions in energy
consumption and waste (the formation of >25 kilograms of waste for every kilogram of product is
commonplace in current pharmaceutical syntheses). This collaborative research project will seek to exploit
recent advances in metal-catalyzed synthetic methodology made by the applicant's research group, in
addressing specific challenges faced by the industrial partner with regard to the preparation of a promising class
of nitrogen-containing heterocyclic compounds. Success in this project will greatly accelerate the industrial
partner's drug development program, thereby leading to more rapid identification of novel therapies to the
benefit of all Canadians.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Nova Scotia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
428983-2011
Name nom
Stradiotto, Mark
Department département
Chemistry
Organization id
79
Institution établissement
Dalhousie University
Province en
Nova Scotia
Province fr
Nouvelle-Écosse
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2011
Competition year année de concours
2011
Award amount
24500
Program id
EGP
Program nane en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1551
Committee name en
Atlantic Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Atlantique
Area of application code
500
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Manufacturing processes and products
Area of application fr
Procédés et produits industriels
Research subject code
3704
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Synthetic methodology
Research subject fr
Méthodologie en synthèse
Partie
1
Nb partie
1
Application title
Direct Preparation of Key Intermediates in Heterocycle Synthesis Employing Novel Pd-Catalyzed Alpha-Arylation
Keyword
NSERC
Application summary
The majority of pharmaceutical compounds derive their beneficial properties from the presence of a
nitrogen-containing heterocyclic core structure. As such, the development of novel routes to such heterocyclic
structural motifs, or their direct precursors, represents an important challenge in the quest to advance the drug
discovery process. Furthermore, the establishment of synthetic protocols that are efficient and modular in
nature, and that exploit cheap and abundant reagents, are particularly attractive in terms of streamlining and
diversifying the assembly of heterocyclic core structures, as well as in facilitating reductions in energy
consumption and waste (the formation of >25 kilograms of waste for every kilogram of product is
commonplace in current pharmaceutical syntheses). This collaborative research project will seek to exploit
recent advances in metal-catalyzed synthetic methodology made by the applicant's research group, in
addressing specific challenges faced by the industrial partner with regard to the preparation of a promising class
of nitrogen-containing heterocyclic compounds. Success in this project will greatly accelerate the industrial
partner's drug development program, thereby leading to more rapid identification of novel therapies to the
benefit of all Canadians.